ft 23 mar 94 survey pharmaceut 4 speed imper cut time take bring new molecul market remain one industri import prioriti bring drug market imper speed product market say dr stephen carter senior vice presid worldwid clinic research develop deal finit patent life market drug exclus period gain return invest even cost front save time worth hundr million dollar need acceler drug develop becom even acut last 12 month accord dr edward scolnick presid merck research laboratori cost contain therapeut substitut shorten effect patent life explain look pravachol mevacor two cholesterol drug compet price although patent still valid lost effect patent life bristol myer squibb capoten come patent expect healthcar compani will pay differ competitor product vasotec even though prescrib best medicin lose effect patent difficulti although drug group want bring product market quickli possibl regulatori hurdl face increas time regulatori process becom increasingli complex demand say dr carter take fact trial use activ control compound compar new molecul old one show drug work show work better exist therapi often mean larg trial involv larg number patient fact regulatori author ask clinic end point rather surrog marker add requir health econom data becom realli expens time consum lament dr carter admit one counter trend us food drug administr willing acceler approv life threaten diseas aid avail therapi except argu anoth problem co ordin develop worldwid basi cost develop high longer possibl achiev reason return european japanes us market rhone poulenc rorer taken board throw resourc intern develop taxoter new cancer compound file new drug applic north america europ japan within three month never done say mr robert cawthorn chief execut dr trevor jone wellcom director research develop medic explain five year ago japan even agenda compani central part think 65 clinic scientist work phase iii trial similarli japanes group fujisawa busi tri establish intern develop capabl bristol myer squibb reach stage prepar one core dossier europ us long time ago use file new drug applic us look europ know requir individu market far effici core dossier say dr carter bristol myer squibb prepar assay european us regulatori author conduct japanes standard even though drug may never develop market decid take product japan save us 18 month say one import element achiev speed market ensur compound pick develop good one benefit drug increment rather dramat approv becom lot tougher major breakthrough much quicker say dr carter compound chosen r amp director face problem alloc scarc resourc compet project prioritis otherwis dead say dr carter dollar spent useless compound x mean fewer dollar spent potenti blockbust drug group develop far fewer compound past bristol myer squibb reckon cut number compound pipelin third recent year upjohn number compound develop cut 74 three year ago 34 accord dr john mccall execut director discoveri research cut drug develop easi howev realli easi start programm say dr william scott senior vice presid exploratori drug discoveri research bristol myer squibb difficult part know kill set stringent go go decis make decis earli possibl save lot time money way tough want add portfolio much possibl make rich possibl strict criteria make sure compound competit say dr carter explain one hardest problem know say team invest year live come sort altern approach save project alway ask one trial surgic put bullet brain turn someth els cultur say person fail project fail human natur tend believ deni success help career develop compound chosen resourc must alloc sir richard syke glaxo chief execut explain prioriti molecul get market quickli possibl take neuraminidas inhibitor treat flu import get 100 per cent attent spare expens bring drug system alloc resourc make judgment import part job say dr scolnick top prioriti drug noth rate limit process develop mevacor cholesterol lower drug fourth biggest sell medicin 1992 concern safeti drug limbo threw resourc half dog alloc test mevacor safeti two drug one rate limit problem manufactur tradit make say 5kg drug trial say dr carter bristol myer squibb trial look good make anoth 5kg potenti blockbust make start past save money hedg bet might take two year longer develop compound plan success rather failur draw design clinic trial stick also import accord dr robert spiegel senior vice presid clinic research schere plough major improv come agre aim start process go sound like clich right first time make sure everyon agre tri make mani chang avoid forc go back scratch start say one techniqu use european us group though japanes one parallel develop dr spiegel explain depend product either wait complet dose rang studi start pivot phase three studi start pivot studi earli use three four dose take resourc realli effect compress telescop process although might accru 50 100 per cent patient might done normal even taken littl longer pivot trial could shave two even three year wait result first dose rang trial howev convinc need first dr roy vagelo chairman chief execut merck say nice first best best ace inhibitor vasotec overtook capoten bristol myer squibb drug better drug noth better clinic trial thorough prepar cut cost see page 7